DrugBank ID:

DB09042

Description:

Drug-resistant bacteria, such as methicillin-resistantStaphylococcus aureus, vancomycin-resistantEnterococcus faecium, and penicillin-resistantStreptococcus penumoniae, represent a massive public health threat.Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approvedlinezolidand is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable thanlinezolid.Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection. [DrugBank]

Targets:

23S ribosomal RNA (Enteric bacteria and other eubacteria) [DrugBank]

Pharmacodynamics:

Tedizolid is an oxazolidinone antibiotic that works by inhibiting protein synthesis by bacterial ribosomes.15,4,7 However, oxazolidinone antibiotics can also bind to human mitochondrial, but not cytoplasmic, ribosomes.5,9 Mitochondrial protein synthesis inhibition is associated with adverse patient effects such as neurological, hematological, and gastrointestinal toxicity, although tedizolid is tolerated better than the related linezolid.3 Alternative therapies should be considered when treating neutropenic patients with ABSSSI. Clostridium difficile-associated diarrhea has been reported in patients treated with tedizolid.15 [DrugBank]

SMILES:

Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1

2D structures:  

3D structures: